Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
CAR T-cell therapies are a form of immunotherapy where some of a patient's T cells are removed, modified in the laboratory to recognize a protein on cancer cells, multiplied, and returned to the patient to provoke an immune attack against cancer. Sometimes the new T cells cause side effects related to the immune system's response to the treatment.
Researchers want to find the best dose of BMS-986453 to treat multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even after treatment.
After people receive chemotherapy for colon cancer, doctors may be able to detect tumor DNA in the blood ("circulating tumor DNA" or ctDNA). If there is ctDNA in the blood, a patient's cancer may be more likely to come back. It is standard for people with ctDNA in their blood to be monitored ("active surveillance"), but investigators would like to know if immediate treatment of these patients can prevent cancer recurrence.
Researchers want to find the best dose of JNJ-79635322 to use in people with multiple myeloma or AL amyloidosis. The people in this study have multiple myeloma or AL amyloidosis that keeps growing even after treatment. Multiple myeloma is a cancer of the bone marrow. AL amyloidosis happens when a protein called amyloid builds up in organs and prevents them from working properly.
Researchers are seeing how well the drug FORE8394 works in people with advanced solid tumors, including brain tumors. The people in this study include adults and children with cancers that keep growing or came back even with treatment. Their tumors have mutations (changes or variants) in the BRAF gene.
Researchers want to find the best dose of lorlatinib to give with ramucirumab in people with lung cancer. They are also seeing how well this drug combination works. The people in this study have non-small cell lung cancer (NSCLC) that has metastasized (spread). In addition, their cancers have a fusion involving the ALK gene. A fusion gene is made when parts of two different genes in your body join together.
Researchers want to learn if the radiopharmaceutical therapy 177Lu-PSMA-617 is a safe treatment for people with glioma. Radiopharmaceutical therapy delivers radiation directly into a tumor to destroy cancer cells.
Deficient mismatch repair (dMMR) happens when a cell becomes unable to repair mistakes that happen during the normal process of cell division. Standard treatments for early-stage rectal cancer include chemotherapy, radiation therapy, and surgery. In this study, researchers are assessing the safety and effectiveness of giving the investigational immunotherapy dostarlimab first in people with locally advanced mismatch repair-deficient rectal cancer. Doctors will then evaluate patients' response to treatment before considering standard chemoradiation and/or surgery. Patients whose tumors respond completely to dostarlimab alone can be followed with close surveillance and no surgery. 
